Related Experiment Video

Updated: Jun 27, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety

Sefi Kronenberg1, Amos Frisch, Beni Rotberg

  • 1Feinberg Child Study Center, Schneider Children's Medical Center of Israel, 14 Kaplan Street, Petach-Tikva, 49202, Israel. sefik@013.net

Pharmacogenomics
|November 21, 2008
PubMed

Insights

Selective serotonin reuptuptake inhibitors (SSRIs) are a first-line treatment for pediatric depression and anxiety, but genetic markers could predict treatment response and side effects. Pharmacogenetic studies aim to identify these markers for personalized medicine.

Area of Science:

  • Pharmacogenetics
  • Neuroscience
  • Pediatric Psychiatry

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for pediatric depression and anxiety.
  • Current SSRI treatment response rates are suboptimal (55-60%), with risks of adverse effects like suicidality.
  • Clinicians lack predictive tools to guide SSRI selection or identify at-risk youth.

Purpose of the Study:

  • To review pharmacogenetic studies on pediatric SSRI treatment.
  • To compare pediatric findings with adult pharmacogenetic data.
  • To identify genetic markers associated with SSRI response and side effects in children.

Main Methods:

  • Comprehensive literature review of pharmacogenetic studies in pediatric populations.
  • Comparison of pediatric pharmacogenetic data with existing adult study results.
  • Focus on genes involved in serotonergic pathways, including the serotonin transporter (5-HTT).

Main Results:

  • Pharmacogenetic research is emerging but limited in pediatric samples.
  • Serotonergic genes, particularly 5-HTT, are key targets for predicting SSRI response.
  • Data suggest potential genetic influences on SSRI efficacy and suicidality risk.

Conclusions:

  • Pharmacogenetics holds promise for personalizing SSRI treatment in pediatric depression and anxiety.
  • Further research is needed to validate genetic markers for clinical use.
  • Identifying genetic predictors can improve treatment outcomes and mitigate risks in youth.

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...